Gene expression identifies heterogeneity of metastatic behavior among gastrointestinal stromal tumors

Keith M Skubitz, Kate Geschwind, Wayne W. Xu, Joe Koopmeiners, Amy P Skubitz

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Adjuvant imatinib is useful in patients with gastrointestinal stromal tumors (GIST) at high risk of recurrence. At present, the risk of recurrence is determined based on tumor size, mitotic rate, tumor site, and tumor rupture. Previous studies using various biochemical pathways identified gene expression patterns that distinguish two subsets of aggressive fibromatosis (AF), serous ovarian carcinoma (OVCA), and clear cell renal cell carcinoma (RCC). These gene sets separated soft tissue sarcomas into two groups with different probabilities of developing metastatic disease. The present study used these gene sets to identify GIST subgroups with different probabilities of developing metastatic disease. Methods: We utilized these three gene sets, hierarchical clustering, and Kaplan-Meier analysis, to examine 60 primary resected GIST samples using Agilent chip expression profiling. Results: Hierarchical clustering using both the combined and individual AF-, OVCA-, and RCC- gene sets identified differences in probabilities of developing metastatic disease between the clusters defined by the first branch point of the clustering dendrograms (p = 0.029 for the combined gene set, p = 0.003 for the AF-gene set, p < 0.001 for the OVCA-gene set, and p = 0.003 for the RCC-gene set). Conclusions: Hierarchical clustering using these gene sets identified at least two subsets of GIST with distinct clinical behavior and risk of metastatic disease. The use of gene expression analysis along with other known prognostic factors may better predict the long-term outcome following surgery, and thus restrict the use of adjuvant therapy to high-risk GIST, and reduce heterogeneity among groups in clinical trials of new drugs.

Original languageEnglish (US)
Article number51
JournalJournal of Translational Medicine
Volume14
Issue number1
DOIs
StatePublished - Feb 13 2016

Fingerprint

Gastrointestinal Stromal Tumors
Gene expression
Tumors
Genes
Gene Expression
Aggressive Fibromatosis
Cluster Analysis
Renal Cell Carcinoma
Carcinoma
Recurrence
Neoplasms
Kaplan-Meier Estimate
Risk-Taking
Set theory
Sarcoma
Surgery
Rupture
Cells
Clinical Trials
Tissue

Keywords

  • GIST
  • Gene expression
  • Heterogeneity
  • Metastasis
  • Microarray
  • Prognosis
  • Sarcoma
  • Subgroups

Cite this

Gene expression identifies heterogeneity of metastatic behavior among gastrointestinal stromal tumors. / Skubitz, Keith M; Geschwind, Kate; Xu, Wayne W.; Koopmeiners, Joe; Skubitz, Amy P.

In: Journal of Translational Medicine, Vol. 14, No. 1, 51, 13.02.2016.

Research output: Contribution to journalArticle

@article{79b5583a65ff497dbb18a90e7f5ba0c2,
title = "Gene expression identifies heterogeneity of metastatic behavior among gastrointestinal stromal tumors",
abstract = "Background: Adjuvant imatinib is useful in patients with gastrointestinal stromal tumors (GIST) at high risk of recurrence. At present, the risk of recurrence is determined based on tumor size, mitotic rate, tumor site, and tumor rupture. Previous studies using various biochemical pathways identified gene expression patterns that distinguish two subsets of aggressive fibromatosis (AF), serous ovarian carcinoma (OVCA), and clear cell renal cell carcinoma (RCC). These gene sets separated soft tissue sarcomas into two groups with different probabilities of developing metastatic disease. The present study used these gene sets to identify GIST subgroups with different probabilities of developing metastatic disease. Methods: We utilized these three gene sets, hierarchical clustering, and Kaplan-Meier analysis, to examine 60 primary resected GIST samples using Agilent chip expression profiling. Results: Hierarchical clustering using both the combined and individual AF-, OVCA-, and RCC- gene sets identified differences in probabilities of developing metastatic disease between the clusters defined by the first branch point of the clustering dendrograms (p = 0.029 for the combined gene set, p = 0.003 for the AF-gene set, p < 0.001 for the OVCA-gene set, and p = 0.003 for the RCC-gene set). Conclusions: Hierarchical clustering using these gene sets identified at least two subsets of GIST with distinct clinical behavior and risk of metastatic disease. The use of gene expression analysis along with other known prognostic factors may better predict the long-term outcome following surgery, and thus restrict the use of adjuvant therapy to high-risk GIST, and reduce heterogeneity among groups in clinical trials of new drugs.",
keywords = "GIST, Gene expression, Heterogeneity, Metastasis, Microarray, Prognosis, Sarcoma, Subgroups",
author = "Skubitz, {Keith M} and Kate Geschwind and Xu, {Wayne W.} and Joe Koopmeiners and Skubitz, {Amy P}",
year = "2016",
month = "2",
day = "13",
doi = "10.1186/s12967-016-0802-3",
language = "English (US)",
volume = "14",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Gene expression identifies heterogeneity of metastatic behavior among gastrointestinal stromal tumors

AU - Skubitz, Keith M

AU - Geschwind, Kate

AU - Xu, Wayne W.

AU - Koopmeiners, Joe

AU - Skubitz, Amy P

PY - 2016/2/13

Y1 - 2016/2/13

N2 - Background: Adjuvant imatinib is useful in patients with gastrointestinal stromal tumors (GIST) at high risk of recurrence. At present, the risk of recurrence is determined based on tumor size, mitotic rate, tumor site, and tumor rupture. Previous studies using various biochemical pathways identified gene expression patterns that distinguish two subsets of aggressive fibromatosis (AF), serous ovarian carcinoma (OVCA), and clear cell renal cell carcinoma (RCC). These gene sets separated soft tissue sarcomas into two groups with different probabilities of developing metastatic disease. The present study used these gene sets to identify GIST subgroups with different probabilities of developing metastatic disease. Methods: We utilized these three gene sets, hierarchical clustering, and Kaplan-Meier analysis, to examine 60 primary resected GIST samples using Agilent chip expression profiling. Results: Hierarchical clustering using both the combined and individual AF-, OVCA-, and RCC- gene sets identified differences in probabilities of developing metastatic disease between the clusters defined by the first branch point of the clustering dendrograms (p = 0.029 for the combined gene set, p = 0.003 for the AF-gene set, p < 0.001 for the OVCA-gene set, and p = 0.003 for the RCC-gene set). Conclusions: Hierarchical clustering using these gene sets identified at least two subsets of GIST with distinct clinical behavior and risk of metastatic disease. The use of gene expression analysis along with other known prognostic factors may better predict the long-term outcome following surgery, and thus restrict the use of adjuvant therapy to high-risk GIST, and reduce heterogeneity among groups in clinical trials of new drugs.

AB - Background: Adjuvant imatinib is useful in patients with gastrointestinal stromal tumors (GIST) at high risk of recurrence. At present, the risk of recurrence is determined based on tumor size, mitotic rate, tumor site, and tumor rupture. Previous studies using various biochemical pathways identified gene expression patterns that distinguish two subsets of aggressive fibromatosis (AF), serous ovarian carcinoma (OVCA), and clear cell renal cell carcinoma (RCC). These gene sets separated soft tissue sarcomas into two groups with different probabilities of developing metastatic disease. The present study used these gene sets to identify GIST subgroups with different probabilities of developing metastatic disease. Methods: We utilized these three gene sets, hierarchical clustering, and Kaplan-Meier analysis, to examine 60 primary resected GIST samples using Agilent chip expression profiling. Results: Hierarchical clustering using both the combined and individual AF-, OVCA-, and RCC- gene sets identified differences in probabilities of developing metastatic disease between the clusters defined by the first branch point of the clustering dendrograms (p = 0.029 for the combined gene set, p = 0.003 for the AF-gene set, p < 0.001 for the OVCA-gene set, and p = 0.003 for the RCC-gene set). Conclusions: Hierarchical clustering using these gene sets identified at least two subsets of GIST with distinct clinical behavior and risk of metastatic disease. The use of gene expression analysis along with other known prognostic factors may better predict the long-term outcome following surgery, and thus restrict the use of adjuvant therapy to high-risk GIST, and reduce heterogeneity among groups in clinical trials of new drugs.

KW - GIST

KW - Gene expression

KW - Heterogeneity

KW - Metastasis

KW - Microarray

KW - Prognosis

KW - Sarcoma

KW - Subgroups

UR - http://www.scopus.com/inward/record.url?scp=84957649402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957649402&partnerID=8YFLogxK

U2 - 10.1186/s12967-016-0802-3

DO - 10.1186/s12967-016-0802-3

M3 - Article

VL - 14

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 51

ER -